Treatment with SGLT2 inhibitors was observed to modestly improve insulin sensitivity by ∼25% to 30% in diabetic animal experimental models [247] and clinical T2DM studies [248] within 2 weeks of treatment initiation. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.